Avnish Bhatia, MD
Hematology & Oncology · Philadelphia, PANPI 1528273760
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 25.1% of the total. Reporting peaked in 2023 at $160 and has fallen 88.1% since, to $19 in 2025. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 22 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$110
- Novartis$88
- E.r. Squibb & Sons, L.L.C.$81
- Eisai Inc.$40
- AstraZeneca$40
- Pfizer$36
- plus $44 from 2 others
Across 35 payments — averaging $7011.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$245K
What the payments were for
- Food & beverage$41795%
- Education$225%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 5 | $110 |
| Novartis | 5 | $88 |
| E.r. Squibb & Sons, L.L.C. | 3 | $81 |
| Eisai Inc. | 2 | $40 |
| AstraZeneca | 2 | $40 |
| Pfizer | 2 | $36 |
| GSK | 2 | $31 |
| Gilead | 1 | $13 |
How this compares
$438 in reported general payments places this provider in the 30th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $12,555 |
| Imatinib Mesylate | 14 | $2,908 |
| Betamethasone Valerate | 13 | $622 |
| Prochlorperazine Maleate | 35 | $509 |
| Dexamethasone | 34 | $469 |
| Anastrozole | 11 | $378 |
| Ondansetron Hcl | 40 | $315 |
| Hydroxyurea | 11 | $266 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $250 |
| Lansoprazole | 14 | $241 |
| Tramadol Hcl | 19 | $182 |
| Ondansetron OdtOndansetron | 14 | $111 |
| Oxycodone Hcl | 11 | $95 |
| Baclofen | 21 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $12,55518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.